Beyond AML, FLT3 reportedly is also expressed in B-ALL (e.g., [19]), which led us to reason that targeting FLT3 might constitute a promising immunotherapeutic strategy also for this disease. This evidence concerns the gene FLT3 and acute myeloid leukemia.